SEC Company Response from Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524) (JAZZ) — May 31, 2007
Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524)
Date: May 31, 2007 · CIK: 0001232524 · Accession: 0001193125-07-126481
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-141164
Letter
Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Re:
Dear Sir/Madam:
In connection with the proposed offering of the above-captioned securities, we, as representatives of the several underwriters, hereby join with the request of Jazz Pharmaceuticals, Inc. (“the Company”) that the effective date of the above-captioned Registration Statement be accelerated so that the same will become effective on May 31, 2007, at 4:00 p.m. Eastern Daylight Time, or as soon as practicable thereafter.
The following is supplemental information supplied under Rule 418(a)(7) under the Securities Act of 1933:
(i)
Date of preliminary prospectus: May 17, 2007
(ii)
Dates of Distribution: May 17, 2007, through the date hereof
(iii)
Number of prospective underwriters to whom the preliminary prospectus was furnished: 4
(iv)
Number of prospectuses so distributed: approximately 8,194
(v)
Number of prospectuses distributed to others, including the Company, the Company’s counsel and independent accountants, and underwriters’ counsel: approximately 205
(vi)
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934.
Very truly yours,
MORGAN STANLEY & CO. INCORPORATED
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request May 31, 2007 Re: Jazz Pharmaceuticals, Inc. Common Stock Registration Statement on Form S-1 No. 333-141164 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Dear Sir/Madam: In connection with the proposed offering of the above-captioned securities, we, as representatives of the several underwriters, hereby join with the request of Jazz Pharmaceuticals, Inc. (“the Company”) that the effective date of the above-captioned Registration Statement be accelerated so that the same will become effective on May 31, 2007, at 4:00 p.m. Eastern Daylight Time, or as soon as practicable thereafter. The following is supplemental information supplied under Rule 418(a)(7) under the Securities Act of 1933: (i) Date of preliminary prospectus: May 17, 2007 (ii) Dates of Distribution: May 17, 2007, through the date hereof (iii) Number of prospective underwriters to whom the preliminary prospectus was furnished: 4 (iv) Number of prospectuses so distributed: approximately 8,194 (v) Number of prospectuses distributed to others, including the Company, the Company’s counsel and independent accountants, and underwriters’ counsel: approximately 205 (vi) We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934. Very truly yours, MORGAN STANLEY & CO. INCORPORATED Acting severally on behalf of themselves and the several Underwriters By: /s/ Bryan W. Andrzejewski Name: Bryan W. Andrzejewski Title: Executive Director [Underwriters Acceleration Request]